Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

82 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-30

Study Completion Date

2027-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Assess response to treatment in children with bronchial asthma attending Assiut university children hospital.
* Role of comorbidities in controlling symptoms of bronchial asthma.
* Evaluate the role of the soluable interleukin 5 receptor, I C-telopeptide of type I collagen (ICTP), miR-223-3p and miR-191-5p in bronchial asthma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation

NCT07011394

Diagnosis Inflammation Asthma in Children +1 more

RECRUITING

Asthma in Children

NCT01286532

Asthma

COMPLETED

Some Biomarkers in Bronchial Asthma in Children

NCT04175093

Bronchial Asthma

UNKNOWN

Defining the Severe Paediatric Asthma Endotype

NCT04680117

Severe Asthma

UNKNOWN NA

Azithromycin for Children Hospitalized With Asthma

NCT02003911

Asthma

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Asthma is a heterogenous disease usually characterized by chronic air way inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough. Asthma affects approximately 300 million people around the world causing about 1,000 deaths per day.

The overall prevalence of asthma among children and adolscents in Eastern Mediterranean Regional Office (EMRO) countries was 10.61%, Among the countries studied, Qatar exhibited the highest prevalence at 16.69%, Egypt (8.85%), Adolescents showed a slightly higher prevalence of asthma at 10.10% compared to children at 9.70%. Boys exhibited a higher prevalence at 11.48% compared to girls at 9.75%. Urban areas demonstrated a higher prevalence at 11.27% than rural areas at 8.29%.

In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the genetic background, but mainly to the effect of a wide number of environmental risk factors, many of which included under the umbrella of "modern lifestyle". However, the worldwide economic globalization could also have contributed to a significant increase in the asthma burden, even in developing countries that presented a low disease prevalence in the recent past.

Severe asthma is an important health burden as children with severe asthma are prone to medication related side effects, life threatening exacerbations, and impaired quality of life. Progressive air flow limitation is also a feature of severe asthma. Most importantly, poor asthma control leads to poor quality of life in children and caregivers.

Comorbidities such as cardiovascular, metabolic, endocrine, respiratory, and psychiatric diseases are prevalent in asthma, owing to chronic inflammation, systemic corticosteroid use, reduced physical activity, and poor sleep.

These comorbidities may obscure asthma diagnosis by mimicking the symptoms of the disease and can influence management, owing to the effects of the treatments of the comorbidities on asthma or of asthma therapy on the comorbid conditions.

Comorbidities with a major impact are rhinitis (particularly in its allergic form), which causes inflammation of the upper airways and can contribute to exacerbate asthma, gastroesophageal reflux (GERD), which may aggravate airway inflammation, obesity, which not only affects respiratory mechanics but induces a systemic proinflammatory status; and, bronchiectasis, which exposes the patient to an increased risk for exacerbations owing to pulmonary infections.

In addition to these, environmental allergen control is an important contributor to poor asthma control. Ongoing allergen or irritant exposure at home or school will end up with difficult to treat asthma.

Addressing comorbidities of asthma is very important for better asthma control. increased BMI, GERD, sinusitis are significantly associated with exacerbation frequency. Evaluation for those disorders should be considered.

Identifying how comorbidities affect disease control in different groups of patients will allow a more personalized approach, focusing on the treatment of individual characteristics and avoiding escalation to maximal therapy.

Asthma is a heterogenous disease in which age of onset has emerged as an important determinant of different phenotypes. Childhood-onset asthma is approximately 70% atopic, with T-helper-2 (Th2) type of airway inflammation, corticosteroid treatment responsiveness, and a good prognosis.

Th2-type cytokines, such as interleukin 4 (IL-4), IL-5, and IL-13, are thought to drive the disease pathology in patients with asthma and play a role in driving many of the hallmarks of allergic inflammation. IL-5 is the critical molecular switch for developing, migrating, and recruiting eosinophils to the lung during allergic inflammation. IL-5 exerts its biological actions via stimulation of the IL-5 receptor expressed by eosinophils, and to a lesser extent, also by basophils.

A range of biomarkers have been identified for the high TH2 asthma, but biomarkers for non-TH2 asthma endotype, also known as the non-eosinophilic asthma endotype, are lacking. However, sputum neutrophils, blood neutrophils, and IL-17 have been proposed as markers for the noneosinophilic endotype.

During airway tissue remodeling, subepithelial fibrosis leads to an altered extracellular matrix (ECM) content, contributing to asthma's pathogenesis . The existence of subepithelial fibrosis in asthmatic airways suggests an imbalance between matrix metalloproteinases (MMP) and their inhibitors.

Type I collagen is one of the most abundant collagens in the healthy lung, providing a structural framework for the airway wall. Type I collagen plays a significant constitute in subepithelial fibrosis in asthmatic airways.

MicroRNAs (miRNAs) are small, non-coding RNA molecules with a length of 21-25 nucleotides. MiRNAs can control gene expression by targeting specific mRNAs for degradation or translational repression. MiRNAs bind to a specific sequence at the 3'UTR of the target messenger RNA (mRNA). The complementary sequences between miRNA and mRNA are usually not fully overlapping, implicating that each miRNA can regulate hundreds of target genes and that several miRNAs can target the same mRNAs.

MiR-223 has a crucial role in innate immunity, myeloid cell differentiation, and cell homeostasis and has several targets that are involved in pathways implicated in the pathogenesis of both asthma and COPD. Finally, miR-223 is easily detectable in multiple human samples (e.g., sputum, bronchial biopsies, and blood) and could therefore serve as a potential biomarker.

levels of miR-191-5p was upregulated in extracellular vehicles (EVs) derived from individuals with asthma, indicating a possible association with both lung function deterioration and inflammation . EVs, as intercellular communication and delivery systems, can play key roles in different pathological and physiological body functions. Research has indicated that EVs containing miR-191-5p may promote inflammatory responses, aggravating asthma symptoms by activating the NF-κB pathway.

Effective asthma management involves a holistic approach addressing both pharmacological and non-pharmacological management, as well as education and self-management aspects. Working in partnership with children and families is key in promoting good outcomes. Education on how to take treatment effectively, trigger avoidance, modifiable risk factors and actions to take during acute attacks via personalised asthma action plans is essential.

All children aged 5 years or younger with asthma or suspected asthma should be provided with inhaled SABA for relief of symptoms. Regular daily low dose ICS is recommended as initial treatment to control asthma in children aged 5 years or For children 6-11 years with asthma symptoms that are well controlled on low dose ICS or who are using SABA alone and have symptoms less than twice aweek, the recommended treatment is taking ICS whenever SABA is taken.

The use of these inhalers have been shown to reduce the risk of asthma attacks and emergency department (ED) admissions, improve lung function and decrease the need for reliever therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchial Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

comparing the mean of FEV1 between two independent groups(comorbidity in bronchial asthma )

Short Acting Beta 2 Agonist

Intervention Type DRUG

short acting drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Short Acting Beta 2 Agonist

short acting drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 6-12 years diagnosed asthma, inpatient or attending pediatric outpatient clinic of Assiut university children hospital.

Exclusion Criteria

* \- Chronic respiratory illness other than asthma (e.g., bronchiectasis, CF)
* Known immunodeficiency or systemic illness
* patients with skeletal deformities
* patients suspected inborn errors of metabolism

Minimum Eligible Age

6 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No